Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · May 12, 2020

Cutaneous Adverse Events as a Predictor of Tumor Response Under Anti-PD-1 Therapy for Metastatic Melanoma

Journal of the European Academy of Dermatology and Venereology: JEADV

 

Additional Info

Journal of the European Academy of Dermatology and Venereology: JEADV
Cutaneous Adverse Events: A Predictor of Tumour Response Under Anti-PD-1 Therapy for Metastatic Melanoma, A Cohort Analysis of 189 Patients
J Eur Acad Dermatol Venereol 2020 Feb 20;[EPub Ahead of Print], L Bottlaender, M Amini-Adle, D Maucort-Boulch, P Robinson, L Thomas, S Dalle

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading